Literature DB >> 3105391

Collagens in neurofibromas and neurofibroma cell cultures.

J Peltonen, R Penttinen, H Larjava, H J Aho.   

Abstract

Neurofibromas contain approximately 30-50% collagen of their lipid-free dry weight, which is about half of the value of skin but approximately twice that described for peripheral nerve endoneurium. Immunohistochemical stainings indicate that neurofibromas contain types I, III, IV, and V collagens and fibronectin. Most of the neurofibroma cells are type IV collagen and S-100 protein positive, which provides immunohistochemical evidence that neurofibromas are mostly composed of Schwann cell-like cells. The proteoglycan/collagen ratio is 4 to 10 times higher in the neurofibromas than in the surrounding dermal tissue. This would explain the typical soft consistency of the neurofibromas and may contribute to a favorable milieu for tumor growth. Pure fibroblastic cell cultures are obtained from neurofibromas after repeated passages. The cultured cells synthesized type I and III collagens and fibronectin, indicating that these cells are important in the production of the fibrous connective tissue proteins in neurofibromas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3105391     DOI: 10.1111/j.1749-6632.1986.tb48079.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

1.  The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts.

Authors:  R P Atit; M J Crowe; D G Greenhalgh; R J Wenstrup; N Ratner
Journal:  J Invest Dermatol       Date:  1999-06       Impact factor: 8.551

Review 2.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

3.  Type 1 neurofibromatosis: selective expression of extracellular matrix genes by Schwann cells, perineurial cells, and fibroblasts in mixed cultures.

Authors:  S Jaakkola; J Peltonen; V Riccardi; M L Chu; J Uitto
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.

Authors:  Andrew S McDaniel; Jayme D Allen; Su-Jung Park; Zahara M Jaffer; Elizabeth G Michels; Sarah J Burgin; Shi Chen; Waylan K Bessler; Clemens Hofmann; David A Ingram; Jonathan Chernoff; D Wade Clapp
Journal:  Blood       Date:  2008-09-02       Impact factor: 22.113

5.  Comparison of various basement membrane components in benign and malignant peripheral nerve tumours.

Authors:  S Haraida; A G Nerlich; K Bise; I Wiest; E Schleicher
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  Plasticity of integrin expression by nerve-derived connective tissue cells. Human Schwann cells, perineurial cells, and fibroblasts express markedly different patterns of beta 1 integrins during nerve development, neoplasia, and in vitro.

Authors:  L L Hsiao; J Peltonen; S Jaakkola; H Gralnick; J Uitto
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

7.  Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.

Authors:  Gaku Tsuji; Ayako Takai-Yumine; Takahiro Kato; Masutaka Furue
Journal:  Cell Death Dis       Date:  2021-05-19       Impact factor: 8.469

Review 8.  Tumorigenesis in neurofibromatosis type 1: role of the microenvironment.

Authors:  Chunhui Jiang; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2021-08-03       Impact factor: 9.867

9.  Perineurial cells coexpress genes encoding interstitial collagens and basement membrane zone components.

Authors:  S Jaakkola; J Peltonen; J J Uitto
Journal:  J Cell Biol       Date:  1989-03       Impact factor: 10.539

Review 10.  Translating current basic research into future therapies for neurofibromatosis type 1.

Authors:  Jean-Philippe Brosseau; Chung-Ping Liao; Lu Q Le
Journal:  Br J Cancer       Date:  2020-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.